Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2143-2152

  Tanaka, Kousuke ^a   Ishikawa, Satoru ^a   Matsui, Yasunori ^a   Kawanishi, Takashi ^a   Tamesada, Makoto ^a   Harashima, Nanae ^b   Harada, Mamoru ^b  

^a Kobayashi Pharmaceutical Co   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Biological response modifier; Cytotoxic T lymphocyte; Immunotherapy; Melanoma; Regulatory T cells; Tumor peptide vaccine

Indexed keywords

LENTINULA EDODES EXTRACT; PEPTIDE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; LYMPH NODE; MELANOMA; MELANOMA B16; MONOTHERAPY; MOUSE; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE; SPLEEN;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EATING; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SHIITAKE MUSHROOMS; SKIN NEOPLASMS; SPLEEN; T-LYMPHOCYTES, REGULATORY; VACCINES, SUBUNIT;

EID: 84870981685     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1275-8     Document Type: Article

References (29)

1. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
2. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells. Nat Med 4:328-332
3. Jager E, Gnjatic S, Nagata Y et al (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1? cancers. Proc Natl Acad Sci USA 97:12198-12203
4. Oka Y, Tsuboi A, Fujiki F et al (2009) WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Aqents Med Chem 9:787-797
5. Mine T, Sato Y, Noguchi M et al (2004) Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptidespecific cellular responses. Clin Cancer Res 10:929-937
6. Schwartzentruber DJ, Lawson DH, Richards JM et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119-2127
7. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915
8. Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16: 115-123
9. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506
10. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
11. Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543
12. Loeffler M, Kruger JA, Reisfeld RA (2005) Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65:5027-5030
13. Wada S, Yoshimura K, Hipkiss EL et al (2009) Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 69:4309-4318
14. Ghiringhelli F, Larmonier N, Schmitt E et al (2004) CD4+ CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344
15. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133
16. Tawara I, Take Y, Uenaka A, Noguchi Y, Nakayama E (2002) Sequential involvement of two distinct CD4+regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 93:911-916
17. Yamaguchi T, Hirota K, Nagahama K et al (2007) Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27:145-159
18. Tanaka K, Ishikawa S, Matsui Y, Tamesada M, Harashima N, Mamoru H (2011) Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Sci 102:516-521
19. Harada M, Tamada K, Abe K et al (1998) Characterization of B16 melanoma-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 47:198-204
20. Kojima H, Akaki J, Nakajima S, Kamei K, Tamesada M (2010) Structural analysis of glycogen-like polysaccharides having macrophage-activating activity in extracts of Lentinula edodes mycelia. J Nat Med 64:16-23
21. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989-994
22. Kato Y, Adachi Y, Ohno N (2008) Characterization of rat betaglucan receptor dectin-1. Microbiol Immunol 52:418-428
23. Manicassamy S, Ravindran R, Deng J et al (2009) Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med 15:401-409
24. Muraoka D, Kato T, Wang L et al (2010) Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 185:3768-3776
25. Zhou LD, Zhang QH, Zhang Y, Liu J, Cao YM (2009) The shiitake mushroom-derived immuno-stimulant lentinan protects against murine malaria blood-stage infection by evoking adaptive immune-responses. Int Immunopharmacol 9:455-462
26. Lu H, Yang Y, Gad E et al (2011) Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8T cells and NK cells. Clin Cancer Res 17: 67-76
27. Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM (2007) TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 245:103-110
28. Yoshioka Y, Tamesada M, Nagayama A (2009) The safety of excessive intake of the food containing extract of cultured Lentinula edodes mycelia (LEM) in healthy adult volunteers. JCAM 6:9-15 (in Japanese)
29. Yoshioka Y, Matsui Y, Kobayashi M et al (2010) Safety evaluation of extract from cultured Lentinula edodes mycelia; study of acute toxicity, genotoxicity and inhibiting effect of drug-metabolizing enzyme, cytochrome P-450 3A4. JCAM 7:51-57 (in Japanese)